Recursion (RXRX) | Financial Analysis & Statements
Recursion Pharmaceuticals Inc. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
35.4M
Gross Profit
21.1M
59.62%
Operating Income
-108.3M
-306.45%
Net Income
-108.1M
-305.85%
Balance Sheet Metrics
Total Assets
1.5B
Total Liabilities
343.3M
Shareholders Equity
1.1B
Debt to Equity
0.30
Cash Flow Metrics
Operating Cash Flow
-41.7M
Free Cash Flow
-47.3M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Recursion Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 74.3M | 58.5M | 43.9M | 39.7M | 10.0M |
| Cost of Goods Sold | 71.0M | 45.2M | 42.6M | 48.3M | 0 |
| Gross Profit | 3.3M | 13.2M | 1.3M | -8.6M | 10.0M |
| Gross Margin % | 4.4% | 22.7% | 2.9% | -21.7% | 100.0% |
| Operating Expenses | |||||
| Research & Development | 475.3M | 314.4M | 241.2M | 155.7M | 135.3M |
| Selling, General & Administrative | 176.6M | 178.2M | 110.8M | 81.6M | 57.7M |
| Other Operating Expenses | -425.0K | -351.0K | -699.0K | -162.0K | -178.0K |
| Total Operating Expenses | 651.4M | 492.3M | 351.3M | 237.1M | 192.8M |
| Operating Income | -648.1M | -479.0M | -350.1M | -245.7M | -182.8M |
| Operating Margin % | -872.8% | -819.0% | -797.8% | -619.3% | -1,827.8% |
| Non-Operating Items | |||||
| Interest Income | 22.8M | 15.8M | 19.1M | 6.3M | 73.0K |
| Interest Expense | 1.8M | 1.6M | 97.0K | 55.0K | 3.0M |
| Other Non-Operating Income | -17.7M | 30.0K | -1.1M | 52.0K | -825.0K |
| Pre-tax Income | -644.9M | -464.8M | -332.1M | -239.5M | -186.5M |
| Income Tax | -136.0K | -1.1M | -4.1M | 0 | 0 |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -644.8M | -463.7M | -328.1M | -239.5M | -186.5M |
| Net Margin % | -868.3% | -792.7% | -747.7% | -603.5% | -1,864.8% |
| Key Metrics | |||||
| EBITDA | -559.4M | -426.7M | -307.6M | -227.7M | -174.3M |
| EPS (Basic) | $-1.44 | $-1.69 | $-1.58 | $-1.36 | $-1.49 |
| EPS (Diluted) | $-1.44 | $-1.69 | $-1.58 | $-1.36 | $-1.49 |
| Basic Shares Outstanding | 447446109 | 274207146 | 207853702 | 175537487 | 125348110 |
| Diluted Shares Outstanding | 447446109 | 274207146 | 207853702 | 175537487 | 125348110 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Recursion Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 743.3M | 594.4M | 391.6M | 549.9M | 285.1M |
| Short-term Investments | - | - | - | 0 | 231.4M |
| Accounts Receivable | - | - | - | 0 | 34.0K |
| Inventory | - | - | - | - | - |
| Other Current Assets | 28.6M | 67.7M | 40.2M | 15.9M | 7.5M |
| Total Current Assets | 812.8M | 714.3M | 438.1M | 569.8M | 534.7M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 158.7M | 193.1M | 93.8M | 80.8M | 33.1M |
| Goodwill | 634.2M | 633.6M | 140.6M | 2.9M | 3.0M |
| Intangible Assets | 309.9M | 335.9M | 36.4M | 1.3M | 1.4M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 19.7M | 16.4M | 6.9M | 7.9M | 8.7M |
| Total Non-Current Assets | 661.3M | 734.3M | 215.6M | 131.5M | 75.6M |
| Total Assets | 1.5B | 1.4B | 653.7M | 701.3M | 610.3M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 18.1M | 21.6M | 4.0M | 4.6M | 2.8M |
| Short-term Debt | 21.8M | 22.2M | 6.2M | 6.0M | 1.5M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 147.7M | 187.5M | 93.2M | 100.3M | 46.7M |
| Non-Current Liabilities | |||||
| Long-term Debt | 56.2M | 86.3M | 44.5M | 45.0M | 10.0M |
| Deferred Tax Liabilities | 23.3M | 16.6M | 1.3M | 0 | - |
| Other Non-Current Liabilities | 2.1M | 4.7M | - | - | - |
| Total Non-Current Liabilities | 195.6M | 226.3M | 97.1M | 115.2M | 20.7M |
| Total Liabilities | 343.3M | 413.8M | 190.3M | 215.5M | 67.4M |
| Equity | |||||
| Common Stock | 5.0K | 4.0K | 2.0K | 2.0K | 2.0K |
| Retained Earnings | -2.1B | -1.4B | -967.6M | -639.6M | -400.1M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 1.1B | 1.0B | 463.4M | 485.8M | 542.9M |
| Key Metrics | |||||
| Total Debt | 78.0M | 108.5M | 50.7M | 51.0M | 11.5M |
| Working Capital | 665.1M | 526.8M | 345.0M | 469.5M | 488.1M |
Balance Sheet Composition
Recursion Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -644.8M | -463.7M | -328.1M | -239.5M | -186.5M |
| Depreciation & Amortization | 83.7M | 36.5M | 24.4M | 11.8M | 8.4M |
| Stock-Based Compensation | 111.2M | 81.7M | 53.5M | 27.9M | 14.8M |
| Working Capital Changes | -26.4M | -43.3M | -59.7M | 105.0M | -13.6M |
| Operating Cash Flow | -422.4M | -364.5M | -298.4M | -86.3M | -172.8M |
| Investing Activities | |||||
| Capital Expenditures | -6.5M | -13.7M | -12.0M | -37.1M | -39.8M |
| Acquisitions | -4.4M | 277.1M | 1.8M | 0 | 0 |
| Investment Purchases | -3.8M | - | 0 | 0 | -301.1M |
| Investment Sales | 0 | 0 | 480.0K | 230.6M | 69.2M |
| Investing Cash Flow | -14.7M | 263.4M | -9.6M | 193.5M | -271.7M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | 0 | 0 |
| Debt Repayment | -8.4M | -4.4M | -766.0K | -90.0K | -12.8M |
| Financing Cash Flow | 517.4M | 296.0M | 127.3M | 143.6M | 450.1M |
| Free Cash Flow | -380.4M | -376.2M | -300.3M | -120.9M | -198.4M |
| Net Change in Cash | 80.3M | 194.8M | -180.7M | 250.9M | 5.6M |
Cash Flow Trend
Recursion Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-2.44
Forward P/E
-4.12
Price to Book
1.64
Price to Sales
24.83
PEG Ratio
0.04
Profitability Ratios
Profit Margin
4.45%
Operating Margin
-328.80%
Return on Equity
-59.54%
Return on Assets
-27.72%
Financial Health
Current Ratio
5.50
Debt to Equity
6.89
Beta
1.01
Per Share Data
EPS (TTM)
$-1.44
Book Value per Share
$2.14
Revenue per Share
$0.17
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| RXRX | 1.9B | -2.44 | 1.64 | -59.54% | 4.45% | 6.89 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Capricor | 2.0B | -15.61 | 6.62 | -46.56% | 0.00% | 4.75 |
| Zymeworks | 2.0B | 3.79 | 7.32 | -26.72% | -76.56% | 6.80 |
| Taysha Gene | 1.8B | 2.53 | 7.39 | -68.45% | 0.00% | 28.41 |
Financial data is updated regularly. All figures are in the company's reporting currency.






